Prosecution Insights
Last updated: November 20, 2026

Regina M Deberry, USPTO Patent Examiner

Listed by the USPTO as DEBERRY, REGINA M

Tech Center 1600 • Art Units: 1628 1647 1674 1677

This examiner grants 50% of resolved cases

Analysis

DEBERRY, REGINA M has resolved 605 cases in Tech Center 1600 and Art Unit 1628. The allowance rate is 50.2%, while the interview lift is 30.7%. The median time to allowance is 1237 days. The figures show an allowance rate near one-half of resolved cases and a substantially larger measured association with interviews than the allowance rate alone would suggest.

The listed companies are Hoffmann-La Roche Inc., Arizona Board of Regents on Behalf of Arizona State University, and The Regents of the University of California. The listed firms are FOLEY & LARDNER LLP, SUGHRUE MION, PLLC, and Clark+Elbing LLP - Genentech and Roche. Counsel working in this docket can draw on the identified biotechnology and institutional prosecution history when developing interview and response strategies.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

50.2%
Allow Rate
-9.8% vs TC avg
649
Total Applications
+30.7%
Interview Lift
1237
Avg Prosecution Days
Based on 605 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
18.6%
§102 Novelty
28.8%
§103 Obviousness
37.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18629145 METHOD AND DEVICE FOR DETECTING SIGLEC12 Non-Final OA The Regents of the University of California
18645245 Method for purifying PEGylated erythropoietin Final Rejection Hoffmann-La Roche Inc.
18301180 HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS Non-Final OA HOFFMANN-LA ROCHE INC.
17640293 THERAPEUTIC FUSION PROTEINS Non-Final OA NOVARTIS AG
19542772 ANTI-INTERLEUKIN-11 ANTIBODIES AND METHODS OF USE THEREOF Non-Final OA Boehringer Ingelheim International GmbH
17773886 HIGH SALT LOAD CONDITIONING DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES Final Rejection AMGEN INC.
18032080 FORMULATION FOR WOUND HEALING Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
18041123 METABOLISM-BASED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF TREATMENT Non-Final OA Arizona Board of Regents on behalf of Arizona State University
17782469 STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD Non-Final OA OTSUKA PHARMACEUTICAL CO., LTD.
18477010 COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND DENDRITIC CELLS Non-Final OA Novocure GmbH
17327504 METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR Final Rejection SANOFI BIOTECHNOLOGY
18030983 COMPOSITIONS FOR TREATMENT ALOPECIA AREATA, BIOMARKERS FOR TREATMENT SUCCESS AND, METHODS OF USE THEREOF Non-Final OA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
18682310 METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR Non-Final OA Alexion Pharmaceuticals, Inc.
17794724 PHASE SEPARATION SENSORS AND USES THEREOF Non-Final OA THE ROCKEFELLER UNIVERSITY
17279857 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER Final Rejection MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Regina M Deberry's allowance rate?

50.2% of resolved applications examined by Regina M Deberry were allowed (605 resolved cases), compared with 25.9% across Art Unit 1628 over the last five years.

Does an interview help with examiner Regina M Deberry?

This examiner's interview lift is +30.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Regina M Deberry take to allow a patent?

Applications allowed by Regina M Deberry took 1,237 days on average from filing to allowance.

Which art unit does examiner Regina M Deberry work in?

Regina M Deberry examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month